Anti-PI 3 kinase p110 alpha Monoclonal Antibody

Overview

This product is an anti-PIK3CA antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone BEB-16; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, ICC, IF, IP (as provided in the source record). Boster Bio Anti-PI 3 kinase p110 alpha Monoclonal Antibody catalog # M00029. Tested in WB, ICC/IF, IP applications. This antibody reacts with Human, Mouse, Rat.

Key elements and design rationale

• Target: PIK3CA (Signal transducer and activator of transcription 3).
• Antibody format: Monoclonal; clone BEB-16; isotype Rabbit IgG.
• Host: Rabbit.
• Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

PIK3CA (protein: P2X purinoceptor 1) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF and other growth factors. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the interleukin-6 (IL-6)- responsive elements identified in the promoters of various acute- phase protein genes. Activated by IL31 through IL31RA. Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity. Plays an important role in host defense in methicillin-resistant S.aureus lung infection by regulating the expression of the antimicrobial lectin REG3G (By similarity). . Reported cellular localization context: Cytoplasm. Nucleus. Shuttles between the nucleus and the cytoplasm. Translocated into the nucleus upon tyrosine phosphorylation and dimerization, in response to signaling by activated FGFR1, FGFR2, FGFR3 or FGFR4. Constitutive nuclear presence is independent of tyrosine phosphorylation. Predominantly present in the cytoplasm without stimuli. Upon leukemia inhibitory factor (LIF) stimulation, accumulates in the nucleus. The complex composed of BART and ARL2 plays an important role in the nuclear translocation and retention of STAT3. Identified in a complex with LYN and PAG1. Tissue expression notes (as provided): Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Research relevance and current trends

• Research context keywords from the source record include: Epigenetics and Nuclear Signaling,Signal Transduction,Cancer,Cell Biology,Oncoproteins/Suppressors,Nuclear Signaling Pathways,Oncoproteins,Cell Cycle,Cell Cycle Inhibitors,Kinases/Phosphatases,Protein Phosphorylation,Tyrosine Kinases.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
• Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
• Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.

Workflow ideas (metafield): Validate PIK3CA antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect PIK3CA expression by Western blot in cell or tissue lysates, Localize PIK3CA by immunofluorescence/immunocytochemistry in cultured cells, Enrich PIK3CA by immunoprecipitation from lysates for downstream analysis

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 131 kDa; calculated MW: 88068 MW).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 131 kDa
• Cellular localization (provided): Cytoplasm. Nucleus. Shuttles between the nucleus and the cytoplasm. Translocated into the nucleus upon tyrosine phosphorylation and dimerization, in response to signaling by activated FGFR1, FGFR2, FGFR3 or FGFR4. Constitutive nuclear presence is independent of tyrosine phosphorylation. Predominantly present in the cytoplasm without stimuli. Upon leukemia inhibitory factor (LIF) stimulation, accumulates in the nucleus. The complex composed of BART and ARL2 plays an important role in the nuclear translocation and retention of STAT3. Identified in a complex with LYN and PAG1.
• Tissue details (provided): Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.